We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world.

Learn More

Putting Patients First

We offer resources to help patients and their loved ones navigate some of the complex challenges that follow the words, “You have cancer.”

Learn More
elder_women

Science-Based, Passion-Driven

We are advancing an innovative, high-value product portfolio for patients globally.

Learn More
doctor_and_patient

Passion with Purpose

We work to benefit patients wherever they live by uniting worldwide talent and resources with our vision.

Learn More
people_walking

BeiGene News

September 19, 2022

NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment

Read more

September 19, 2022

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

Read more

September 10, 2022

BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer

Read more

September 7, 2022

BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Read more

August 23, 2022

BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China

Read more

August 15, 2022

BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care

Read more